Home › Compound Library › Alpha-Lipoic Acid (ALA)

Alpha-Lipoic Acid (ALA)

Antioxidantoral · inferred

Both fat- and water-soluble antioxidant that regenerates other antioxidants (vitamins C, E, glutathione). Supports blood sugar management and nerve health. Very short half-life.

Projected serum levels — 600 mg, once daily

Alpha-Lipoic Acid (ALA)
Alpha-Lipoic Acid (ALA) modeled serum levels, 600 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 600 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 85.8 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 600 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antioxidant
Route modeled
Oral
Model confidence
inferred
Half-life
30 min
Common dose
600 mg
Suggested maximum
1.2k mg/day
Reference dose range
300–1.2k mg (single dose)
Suggested cadence
once daily
Validated against
600 mg oral — Cmax 4 mg/L at 0.50 h

Documented interactions

  • caution
    Metformin + Alpha-Lipoic Acid (ALA) Potentiation

    Alpha-lipoic acid enhances insulin sensitivity. Combined with metformin, may increase hypoglycemia risk.

Serum checks 1 modeled interaction pairings for alpha-lipoic acid (ala) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy (ALADIN III) Ziegler D et al. · Diabetes Care, 2006 DOI

    RCT found intravenous alpha-lipoic acid (600 mg/day) significantly reduced neuropathic pain and symptoms in diabetic patients within 3 weeks of treatment.

  2. The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles: a systematic review and meta-analysis of randomized controlled trials Akbari M et al. · Metabolism, 2018 DOI

    Meta-analysis of 24 RCTs found alpha-lipoic acid significantly reduced fasting glucose, insulin, HbA1c, and LDL cholesterol levels.

  3. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R · Diabetes care, 1999 DOI

    This citation reports a human clinical study involving Alpha-Lipoic Acid (ALA). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

3 published studies referenced in the app, each with a plain-language summary.